Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan
Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Anticancer Res. 2019 Aug;39(8):4279-4283. doi: 10.21873/anticanres.13592.
BACKGROUND/AIM: To determine whether concurrent chemotherapy with radiotherapy should be performed in elderly patients with esophageal cancer.
A total of 185 patients aged 80 years or older who were treated with definitive radiotherapy alone or combined with chemoradiotherapy for esophageal cancer at seven institutions were enrolled. In order to compare survival rates of patients treated with chemoradiotherapy with those of patients treated with radiotherapy alone, propensity score matching was performed to homogenize the two populations.
For the whole patient cohort, the 3-year overall survival (OS) rate was 52.6% and the median survival was 42.5 months. After propensity score matching, the 3-year OS rate for the chemoradiotherapy group was not significantly better than that for the group treated with radiotherapy alone (53.7% vs. 59.9%, p=0.876).
Concurrent chemotherapy with radiotherapy for esophageal cancer in patients aged 80 years or older did not have significant OS benefit over radiotherapy alone.
背景/目的:确定在老年食管癌患者中是否应同时进行放化疗。
共纳入了 185 名在 7 家机构接受单纯根治性放疗或放化疗联合治疗的 80 岁及以上食管癌患者。为了比较放化疗组和单纯放疗组患者的生存率,采用倾向评分匹配法使两组人群均衡。
对于全患者队列,3 年总生存率(OS)为 52.6%,中位生存时间为 42.5 个月。经过倾向评分匹配后,放化疗组 3 年 OS 率与单纯放疗组相比没有显著改善(53.7% vs. 59.9%,p=0.876)。
对于 80 岁及以上的食管癌患者,与单纯放疗相比,同时进行放化疗并没有显著的 OS 获益。